A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: DRUG: LY3475070|DRUG: Pembrolizumab
Sponsor: Eli Lilly and Company
Collaborators: Merck Sharp & Dohme LLC